Rocket Lab Stock Has Collapsed 57% From Highs. Here's Why I'm Not Buying (Yet).

Rocket Lab (RKLB) is set to close its $8B (half-stock/half-cash) acquisition of Iridium Communications and is developing the larger Neutron rocket, while its share price is down 57% from recent highs. The article highlights strong momentum in launches (90+ Electron contracts) and a $2.3B backlog, but also notes continued losses with negative free cash flow of $371M over the last 12 months and a very high trailing P/S of 48 vs the S&P 500 average of 3.8. Net: promising growth levers, but investors are urged to wait for a materially lower entry price (possibly ~50% below current levels) given current valuation and profitability timing risk.

Analysis

The market is still pricing RKLB like a scarcity asset, but the economic reality is a long-duration capital project with a financing overhang. Folding in a cash-generative communications business can make reported FCF look less alarming, yet it also raises execution complexity and makes the equity more sensitive to dilution, integration, and timing slippage than to headline backlog. The key inflection is not backlog size; it is whether Neutron and the acquired asset can convert into durable margin without forcing another equity raise.

Competitive dynamics likely remain asymmetric in favor of the incumbent leader, not the aspirant. RKLB may gain credibility as a bundled launch-plus-connectivity supplier, but the more immediate spillover is pressure on listed satellite comm peers and on any customer considering multi-vendor redundancy. If the acquisition closes, the near-term winner is probably the target’s holders via deal value realization; the loser is RKLB equity, which is effectively paying for a lower-cost-of-capital narrative that may not survive a stricter FCF haircut.

Catalysts are mostly binary and time-based: deal-close / financing headlines in days to weeks, Neutron test-flight timing in 1-3 months, and true operating leverage only over 6-18 months. The contrarian miss is that a lower share price does not automatically make the valuation cheap when the denominator is still a years-away revenue base; if the first full test flight slips or capex steps up faster than revenue, the multiple can compress again. What would falsify a bearish stance is a clean close, no incremental dilution, and evidence that Neutron converts from prototype spend to customer launches on schedule.

Key Decisions for Investors

• Fade strength in RKLB: use a 3-6 month bearish put spread or outright short on any rally tied to merger enthusiasm; thesis is invalidated if Neutron executes on schedule and management raises medium-term revenue/FCF guidance.
• Treat IRDM as an event-driven watchlist item only until merger docs confirm terms; if the spread widens on financing or regulatory noise, consider long IRDM / short RKLB as a relative-value trade.
• Avoid adding to broad space-basket exposure via SPCX until there is proof of Neutron launch cadence; the sector proxy still trades more on story momentum than on verifiable cash generation.
• If seeking upside exposure, wait for a post-close or post-test-flight reset rather than paying today’s multiple; current risk/reward still favors patience over initiation.